Sunshine Lake Pharma Co., Ltd.
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
5
Ending by 2030
Jun 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Dec 4 to 20, 2026 · next Dec 4
- 1 fee due Feb 6, 2027The maintenance fee for Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof (US 10,370,380) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
- 1 fee due Mar 15, 2027The maintenance fee for Substituted quinoline compounds and methods of use (US 9,133,162) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 2 fees due May 10 to 19, 2027 · next May 10
- 2 fees due Jun 3 to 10, 2027 · next Jun 3
- 2 fees due Jul 2 to 21, 2027 · next Jul 2
- 2 fees due Aug 11 to 18, 2027 · next Aug 11
- 2 fees due Nov 12, 2027
Recent changes
- 2 of the patents on this record were granted since Aug 18, 2026
- 2 terms have ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US RE44,987 | Bromo-phenyl substituted thiazolyl dihydropyrimidines In force · From the USPTO record | In force | From the USPTO record | |
| US 8,227,511 | Substituted Chromanol Derivatives and Their Use In force · High confidence | In force | High confidence | |
| US RE45,004 | Bromo-phenyl substituted thiazolyl dihydropyrimidines In force · From the USPTO record | In force | From the USPTO record | |
| US 8,426,585 | Compounds comprising a spiro-ring In force · From the USPTO record | In force | From the USPTO record | |
| US 8,293,897 | Compounds comprising a spiro-ring and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 8,232,294 | Amino ester derivatives, sailts thereof and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 9,598,400 | Substituted quinoline compounds and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 9,133,162 | Substituted quinoline compounds and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 9,181,277 | Aminoquinazoline derivatives and their salts and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 9,434,695 | Nitrogenous heterocyclic derivatives and their application in drugs In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 105: 15 patents in force now held by others · 14 lapsed for an unpaid fee · 2 ended at full term · 2 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
22 pending · 3 abandoned · 28 no status recorded